MDT

Over the last six months (approximately April 2026 to October 2026), Medtronic's stock price experienced fluctuations, trading at $88.56 as of October 10, 2026, representing a 3.32% decrease in the past month and a 7.28% decrease over the last 12 months. The 52-week low was $73.31, and the 52-week high was $106.33. Specific events impacting the stock price include earnings reports, with Q4 2026 EPS at $0.960 USD and Q1 2027 EPS at $1.140 USD. New product approvals and launches, such as regulatory milestones and FDA clearances for systems like Altaviva™, Symplicity Spyral™, and the LigaSure™ RAS Maryland instrument on the Hugo™ RAS system, are expected to support growth. A strategic portfolio reshaping was announced in October 2023, with plans to separate its Patient Monitoring and Respiratory Interventions businesses to sharpen focus. Analysts have given Medtronic a consensus rating of 'Moderate Buy' with an average price target of $102.92, suggesting a potential upside of approximately 16.2%.